Posted by Michael Wonder on 09 Mar 2025
Expanded reimbursement for Rinvoq enhances atopic dermatitis treatment options
7 March 2025 - Korean patients with moderate to severe atopic dermatitis now have greater flexibility in treatment as reimbursement has been expanded to allow switching between the biologic agents and the Janus kinase inhibitors.
The expanded reimbursement will especially have a positive impact on AbbVie Korea’s Rinvoq (upadacitinib monohydrate), which can be used for adolescents aged 12 and older under expanded coverage, reinforcing its role in personalised treatment strategies.
